Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma

Authors

Prashant Bavi, King Fahad National Centre for Children's cancer and Research, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211 Saudi Arabia
Jehad Abubaker, King Fahad National Center for Children's Cancer and Research, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211 Saudi Arabia
Azhar Hussain, Aga Khan UniversityFollow
Meher Sultana, King Fahad National Center for Children's Cancer and Research, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211 Saudi Arabia
Fouad Al-Dayel, King Fahad National Center for Children's Cancer and Research, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211 Saudi Arabia,
Shahab Uddin, King Fahad National Center for Children's Cancer and Research, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211 Saudi Arabia
Khawla S. Al-Kuraya, King Fahad National Center for Children's Cancer and Research, King Faisal Specialist Hospital and Research Centre, Riyadh, 11211 Saudi Arabia

Document Type

Article

Department

Centre for Regenerative Medicine

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults, accounting for nearly 40% of all non-Hodgkin's lymphomas. As cell proliferation is essential for tumor growth, analysis of the cell cycle might give additional information on tumor progression. Although markers distinctive for cell-cycle regulation in DLBCL have been addressed, less attention has been paid to cyclin H in DLBCL with respect to its prognostic and potential therapeutic implications. Cyclin H occurs as a component of the cyclin H/Cdk 7/Mat 1 complex. Cyclin H is also a substrate of protein kinase 2, a ubiquitously expressed serine/threonine protein kinase required for cell viability and cell-cycle progression. We evaluated the expression of cyclin H by immunohistochemistry in 301 DLBCLs in a tissue microarray format. Validation was done by performing quantitative real-time polymerase chain reaction and Western blotting experiments for cyclin H. We studied the relationship between cyclin H expression in comparison to other cyclins (A, B1, D1, D3, and E) and the proliferation marker Ki-67. Reduced or absent cyclin H expression was seen in 14.5% of the DLBCL cases. Interestingly, reduced or absent cyclin H expression was correlated with lower expression of proliferation marker Ki-67 (P < .0001), cyclin B1 (P = .0001), cyclin D3 (P = .0007), and cyclin E (P < .0001). Reduced or absent cyclin H expression was significantly associated with poor overall survival, in both the univariate (P = .0286) and multivariate analysis with International Prognostic Index (P = .0180). Our study demonstrates the independent prognostic value of cyclin H expression in DLBCL and proposes its use as a prognostic marker.

Comments

This work was published before the author joined Aga Khan University.

Publication (Name of Journal)

Human Pathology

Recommended Citation

Bavi, P., Abubaker, J., Hussain, A., Sultana, M., Al-Dayel, F., Shahab Uddin, ., S. Al-Kuraya, K. (2008). Reduced or absent cyclin H expression is an independent prognostic marker for poor outcome in diffuse large B-cell lymphoma. Human Pathology, 39(6), 885-894.
Available at: https://ecommons.aku.edu/crm/24